Title
Mortality in young adults following in utero and childhood exposure to arsenic in drinking water.

Permalink
https://escholarship.org/uc/item/40q8f08q

Journal
Environmental Health Perspectives, 120(11)

Authors
SMITH, Allan H.
Marshall, Guillermo
Liaw, Jane
et al.

Publication Date
2012-11-01

DOI
10.1289/ehp.1104867

Peer reviewed
BACKGROUND: Beginning in 1958, the city of Antofagasta in northern Chile was exposed to high arsenic concentrations (870 µg/L) when it switched water sources. The exposure abruptly stopped in 1970 when an arsenic-removal plant commenced operations. A unique exposure scenario like this—with an abrupt start, clear end, and large population (125,000 in 1970), all with essentially the same exposure—is rare in environmental epidemiology. Evidence of increased mortality from lung cancer, bronchiectasis, myocardial infarction, and kidney cancer has been reported among young adults who were in utero or children during the high-exposure period.

OBJECTIVE: We investigated other causes of mortality in Antofagasta among 30- to 49-year-old adults who were in utero or ≤18 years of age during the high-exposure period.

METHODS: We compared mortality data between Antofagasta and the rest of Chile for people 30–49 years of age during 1989–2000. We estimated expected deaths from mortality rates in all of Chile, excluding Region II where Antofagasta is located, and calculated standardized mortality ratios (SMRs).

RESULTS: We found evidence of increased mortality from bladder cancer (SMR = 18.1; 95% confidence interval (CI): 11.3, 27.4), laryngeal cancer (SMR = 8.1; 95% CI: 3.5, 16.0), liver cancer (SMR = 2.5; 95% CI: 1.6, 3.7), and chronic renal disease (SMR = 2.0; 95% CI: 1.5, 2.8).

CONCLUSIONS: Taking together our findings in the present study and previous evidence of increased mortality from other causes of death, we conclude that arsenic in Antofagasta drinking water has resulted in the greatest increases in mortality in adults < 50 years of age ever associated with early-life environmental exposure.

KEY WORDS: arsenic, childhood exposure, Chile, drinking water, environmental exposure, in utero, mortality. Environ Health Perspect 120:1527–1531 (2012). http://dx.doi.org/10.1289/ehp.1104867 [Online 4 September 2012]
1958–1970 (probable in utero and childhood exposure to those born in Antofagasta), and births during 1940–1957 (probable childhood, but not in utero, exposure to those born in Antofagasta).

The Ministry of Health coded causes of death for 1989–1998 using the International Classification of Diseases, 9th Revision (ICD-9; World Health Organization 1978) and for 1999–2000 using the 10th revision (ICD-10; World Health Organization 1992). For our analysis, we converted all ICD-10 codes into ICD-9 codes. In our initial analysis, we noticed that several causes of death listed under ICD-9 codes 580–589 (genitourinary) exhibited elevated standardized mortality ratios (SMRs). The excess deaths were limited to chronic renal failure (ICD-9 code 585), renal failure unspecified (ICD-9 code 586), chronic glomerulonephritis (ICD-9 code 582), and renal sclerosis (ICD-9 code 587). Because each of these causes of death relates to chronic renal disease and renal failure, we grouped them together as mortality from chronic renal disease.

We obtained annual estimates of the population living in Antofagasta in Region II, as well as for the rest of Chile excluding Region II, for 1989–2000 from the National Institute of Statistics (Instituto Nacional de Estadísticas); estimates were stratified by age and sex. We calculated SMRs for deaths among those 30–49 years of age, using 10-year age groups (30–39 and 40–49 years) for age standardization. We calculated significance and confidence intervals (CIs) based on the Poisson distribution (Selvin 1995). In view of the clear direction of the a priori hypotheses for arsenic causing increased risks for both malignant and nonmalignant diseases, here we present one-tailed tests of statistical significance. We tested for effect modification by age group (comparing 30- to 39-year and 40- to 49-year age groups) and effect modification by sex using Poisson regression interaction terms with two-tailed tests. We also tested for effect modification by birth period, comparing mortality for those born in 1940–1949 with those born in 1950–1957, but because there were no significant differences by birth period for any outcome ($p > 0.05$), we report results for both periods combined. We compared mortality at 30–49 years of age among those born in 1940–1957, who would have experienced at least part of their exposure ≤ 18 years of age, with mortality among those born during 1958–1970, most of whom would have been exposed in utero if they were born in Antofagasta.

### Results

Based on a 1990 random sample survey of Chilean cities that included Antofagasta (Caracterizacion Socio Economica Nacional; CASEN 1990), the prevalence of smoking in 1990 was comparable between Antofagasta and the rest of Chile (Table 1). Demographic characteristics for Region II from the 2002 Census (Instituto Nacional de Estadisticas Chile 2002) are similar for Region II and Chile as a whole, including the percentage of the population living in urban areas (98% and 87%, respectively) and the percentage of medically certified death certificates (90% and 86%). Diet and other health risk factors collected in studies of stratified random population census samples conducted in 2003 and 2009 (Gobierno de Chile, Ministerio de Salud 2003, 2010), including obesity, blood cholesterol, glucose, and hypertension, were also similar between the comparison populations.

We first estimated SMRs comparing specific causes of death among adults 30–49 years of age born in Antofagasta during 1940–1970 (both sexes combined) to the same age group born in the rest of Chile (data not shown). We observed no increased mortality from infectious and parasitic diseases (ICD-9 codes 001–139; SMR = 1.0; 95% CI: 0.8, 1.3), endocrine and nutritional diseases (ICD-9 codes 240–279; SMR = 1.2; 95% CI: 0.7, 1.8), for diseases of the respiratory system (ICD-9 codes 460–519; SMR = 1.1; 95% CI: 0.9, 1.3), or diseases of the digestive system (ICD-9 codes 520–579; SMR = 0.8; 95% CI: 0.7, 0.9). Mortality was increased for all cancers combined (ICD-9 codes 140–239; SMR = 1.7; 95% CI: 1.6, 1.9; $p < 0.001$), deaths from circulatory diseases (ICD-9 codes 390–459; SMR = 1.7; 95% CI: 1.5, 2.0; $p < 0.001$), and diseases of the genitourinary system (ICD-9 codes 580–629; SMR = 2.0; 95% CI: 1.5, 2.8; $p < 0.001$).

Table 2 presents the SMRs for selected causes of death in Antofagasta for males and females 30–49 years of age during 1989–2000 and the expected numbers estimated from those in the rest of Chile (excluding Region II). The “all other cancers” category comprises all cancers other than those of the bladder, larynx, and liver, as well as lung and kidney cancers, which we previously reported to be associated with early-life arsenic exposure (Smith et al. 2006; Yuan et al. 2010). Mortality for all cancers combined was increased for males born during 1940–1957, most of whom would have experienced at least some exposure before 18 years of age (SMR = 2.1; 95% CI: 1.9, 2.4; $p < 0.001$), and for those born during the high-exposure period (1958–1970), most of whom would have experienced both in utero and childhood exposure (SMR = 2.2; 95% CI: 1.7, 2.8; $p < 0.001$). Mortality from all cancers combined was also increased among females (SMR = 1.4; 95% CI: 1.2, 1.6 and SMR = 1.4; 95% CI: 1.1, 1.8 for those born in 1940–1957 and 1958–1970, respectively), but to a lesser extent than in males.

Mortality from bladder cancer was greatly increased in males and females (Table 2), particularly among those born during 1958–1970.

### Table 1. Comparing smoking data, demographic variables, and risk factors for Region II (of which Antofagasta constitutes more than half of the total population) with those for all of Chile.

| Variable                        | Region II | All of Chile |
|---------------------------------|-----------|--------------|
| Smoking (%)                     |           |              |
| Nonsmokers                      | 78.0      | 77.5         |
| Moderate smokers (> 0 to 1 pack/day) | 21.0      | 21.1         |
| Heavy smokers (> 1 pack/day)    | 0.0       | 1.2          |
| Men smokers                     | 27.4      | 26.6         |
| Women smokers                   | 16.6      | 19.3         |
| Demographic variable (%)        |           |              |
| Urban                            | 98        | 87           |
| Catholic                        | 72        | 70           |
| Literate                        | 98        | 97           |
| Prebasic education              | 4         | 4            |
| University/professional education| 17        | 14           |
| Death certificate certified by physician | 90 | 86 |
| Medical risk factor             |           |              |
| Average BMI (kg/cm²)            | 27.6      | 26.8         |
| Obese [BMI > 30 (%)]            | 19.2      | 21.9         |
| Morbidly obese [BMI > 40 (%)]   | 2.8       | 1.3          |
| Average HDL cholesterol (mg/dL) | 34.2      | 44.6         |
| Average LDL cholesterol (mg/dL) | 105.0     | 115.4        |
| Hypertension [blood pressure > 140/90 (%)] | 28.9 | 32.5 |
| Average total cholesterol (mg/dL) | 174.0   | 186.0        |
| Average serum glucose (mg/dL)   | 85.8      | 92.9         |
| Diabetes (%)                    | 3.2       | 4.2          |
| Regular exercise (%)            | 13.8      | 9.2          |
| Dietary risk factor in national survey |     |              |
| Alcohol consumed per day (g)    | 41.5      | 55.6         |
| Fruit/vegetables consumed per day (g) | 174.0   | 188.0        |
| Salt consumption/day (g)        | 173.8     | 185.8        |

Abbreviations: BMI, body mass index; HDL, high-density lipoprotein; LDL, low-density lipoprotein.

1. Data from CASEN (1988).
2. Data from Instituto Nacional de Estadísticas Chile (2002).
3. Data from Gobierno de Chile, Ministerio de Salud (2003).
4. Data from Gobierno de Chile, Ministerio de Salud (2010).
In Chile following early-life arsenic exposure (Smith et al. 2006), as well as increases in bronchiectasis in India after adult exposure (Guha Mazumder et al. 2005). We have also reported increases in mortality from kidney cancer (Yuan et al. 2010) and myocardial infarction (Yuan et al. 2007) after early-life exposure to arsenic in Antofagasta. Bladder cancer SMRs from the present analysis for adults (30–49 years of age) born during the high-exposure period (1958–1970; males: SMR = 65.7; 95% CI: 24.1, 143; females: SMR = 43.0; 95% CI: 8.9, 126) are 5–10 times higher than those we reported previously for all ages combined, regardless of age at exposure (males, 6.0; females, 8.2) (Smith et al. 1998).

The association between early-life exposure to arsenic and mortality from laryngeal cancer suggests that this cancer might be related to arsenic exposure, although the number of laryngeal cancer deaths was very small and the association was evident only among men.

The findings concerning mortality from chronic renal disease were unexpected. In one study in Taiwan, Chiu and Yang (2005) reported a relationship between arsenic and mortality from renal diseases, but the authors did not specifically investigate early-life exposure. In the study area in Taiwan, residents had consumed arsenic-contaminated well water with a median concentration of 780 µg/L and had renal disease mortality rates that were 50% higher than those in unexposed populations. It is plausible that renal disease might relate to arsenic in water because arsenic is excreted through the kidney and is also a probable cause of kidney cancer (National Research Council 2001; Yuan et al. 2010).

Discussion

We found increases in mortality from several different causes of death in the 30- to 49-year-old study population. We previously reported increases in lung cancer and bronchiectasis among noncancer causes of death for adults 30–49 years of age, we observed evidence of increased mortality from chronic renal disease, with SMRs in the range of 1.9–2.5 for men and women born during or before the high-exposure period (Table 2).

When data for both time periods were combined, we observed no significant differences in SMRs by sex for outcomes evaluated for the first time in the present study, or for outcomes evaluated previously using SMRs for different time periods or separately for men and women (lung cancer, bronchiectasis, and other chronic obstructive pulmonary disease [COPD] (Smith et al. 2006); acute myocardial infarction (Yuan et al. 2007); and kidney cancer (Yuan et al. 2010)) (Figure 1). The highest SMRs were for bladder cancer (SMR = 18.1; 95% CI: 11.3, 27.4) and bronchiectasis (SMR = 18.4; 95% CI: 10.3, 30.4) (Figure 1).

Table 2. Observed and expected deaths and SMRs for males and females 30–49 years of age during 1989–2000 and born in Antofagasta, Chile, in 1940–1957 and 1958–1970 (during the high-exposure period).

| Cancer                      | Male Observed | Female Observed | Male Expected | Female Expected | Male SMR (95% CI) | Female SMR (95% CI) | p-value | Male Observed | Female Observed | Male Expected | Female Expected | Male SMR (95% CI) | Female SMR (95% CI) | p-value | p for interaction | p for interaction |
|-----------------------------|---------------|-----------------|---------------|-----------------|------------------|--------------------|----------|---------------|-----------------|---------------|-----------------|------------------|--------------------|----------|------------------|-------------------|
| All cancer                  | 226           | 219             | 105.3         | 154.5           | 2.1 (1.9, 2.4)    | 1.4 (1.2, 1.6)     | <0.001   | 69            | 59             | 30.8          | 41.3           | 2.2 (1.7, 2.8)    | 1.4 (1.1, 1.8)     | <0.001  | 0.83             |                   |
| Bladder cancer              | 11            | 2               | 0.8           | 0.3             | 13.7 (8.6, 24.5)  | 7.9 (1.0, 28.6)    | <0.001   | 6             | 3             | 0.1           | 0.1             | 65.7 (24.1, 143)  | 43.0 (8.9, 126)    | <0.001  | 0.01             |                   |
| Laryngeal cancer            | 7             | 2               | 0.8           | 0.3             | 8.9 (3.6, 18.3)   | 7.9 (1.0, 28.6)    | 0.03     | 1             | 3             | 0.0           | 0.0             | 27.4 (7.0, 153)   | 43.0 (8.9, 126)    | <0.001  | 0.01             |                   |
| Liver cancer                | 10            | 6               | 4.1           | 4.1             | 2.4 (1.2, 4.4)    | 1.5 (0.5, 3.2)     | 0.01     | 5             | 4             | 0.9           | 0.9             | 5.9 (1.9, 13.7)   | 4.7 (1.3, 12.0)    | <0.01   | 0.04             |                   |
| All other cancers           | 79            | 174             | 82.9          | 142.1           | 1.0 (0.8, 1.2)    | 1.2 (1.0, 1.4)     | 0.64     | 41            | 48            | 27.7          | 39.0           | 1.5 (1.1, 2.0)    | 1.2 (0.9, 1.6)     | 0.09    | 0.36             |                   |
| Chronic renal disease       | 14            | 14              | 7.5           | 7.1             | 1.9 (1.0, 3.1)    | 2.0 (1.1, 3.3)     | 0.02     | 6             | 6             | 2.7           | 2.4             | 2.3 (0.8, 4.9)    | 2.5 (0.9, 5.4)     | 0.04    | 0.71             |                   |
| All other noncancer deaths  | 310           | 187             | 367.7         | 178.3           | 0.8 (0.8, 0.9)    | 1.0 (0.9, 1.2)     | 0.99     | 110           | 89            | 128           | 61.8           | 0.9 (0.7, 1.0)    | 1.4 (1.2, 1.8)     | <0.01   | 0.33             |                   |

All data presented for Antofagasta include neighboring Mejillones, which had the same water sources.

*aOne-sided p-value. **Two-sided p-value; test for interaction between birth periods 1940–1957 and 1958–1970 adjusted for sex. *All other cancers* comprises all cancers except those of the bladder, larynx, liver, lung, and kidney. **CD-9 codes 580–588. *All other noncancer deaths minus injuries* comprises all noncancer deaths except injuries, acute myocardial infarction, bronchiectasis, and other COPD; the last three of these diseases were previously shown to be associated with early-life arsenic exposure (Smith et al. 2008; Yuan et al. 2007).
Adult liver cancer has been linked to arsenic exposure, primarily in studies in Taiwan (Chiou et al. 2004). In a previous study in Region II of Chile, we found little evidence of increased mortality from liver cancer in adults (Smith et al. 1998), but we did not evaluate early-life exposure. However, in a subsequent analysis of childhood cancers (Liaw et al. 2008), liver cancer mortality in children 10–19 years of age was increased in Region II compared with Region V [for males, relative risk (RR) = 8.9; 95% CI: 1.7, 45.8; p = 0.009; for females, RR = 14.1; 95% CI: 1.6, 126; p = 0.018]. The data we present here are, to our knowledge, the first to link early-life arsenic exposure to liver cancer mortality in adults 30–49 years of age.

A major strength of this study is the large size of the exposed population: There were > 125,000 residents in Antofagasta and Mejillones in 1970 who were exposed to water arsenic concentrations of 870 µg/L, including approximately 60,000 children with early-life exposure during the high-exposure period. The largest cohort study on arsenic conducted in Taiwan involved only 698 subjects ≥ 40 years of age exposed to arsenic concentrations > 300 µg/L (Chiou et al. 2001). Recently published cohort studies in Bangladesh involved 10,431 subjects ≥ 15 years of age exposed to arsenic at 300 µg/L, the largest study (Sohel et al. 2009), and 2,889 subjects ≥ 18 years of age exposed to > 150 µg/L, in the second largest study (Argos et al. 2010). In addition, the populations studied in Taiwan, India, and Bangladesh received their water from a large number of small-town or domestic wells with wide variations in arsenic concentrations, even between closely located wells (Guha Mazumder et al. 1998; Van Geen et al. 2002), making it extremely difficult to accurately estimate early-life exposure decades earlier.

One potential weakness of the present study is that it is ecological, comparing Antofagasta with the rest of Chile. However, this study does not have the usual problems associated with what is sometimes termed the “ecologic fallacy” (Morgenstern 1995) because the one source of drinking water in Antofagasta had a known concentration of arsenic; therefore, we can be confident that virtually everyone who lived in Antofagasta during the high-exposure period was indeed exposed. Migration into and out of the study area could also introduce bias, but people migrating from Antofagasta to elsewhere in Chile would constitute a very small proportion of the total Chilean population. Any resulting bias would tend to reduce relative mortality estimates for Antofagasta. Migration into Antofagasta also would tend to bias estimates toward the null because these residents would be misclassified as exposed even though they did not reside in Antofagasta during the high-exposure period. In addition, migration within Chile is relatively uncommon: From 1965 to 2000, annual internal migration among regions of Chile was only 0.6% compared with 1.2% in Argentina, 3.1% in the United Kingdom, and 6.6% in United States (Soto and Torche 2004).

Another potential weakness of the study is the use of death certificate data. Based on Chile’s Census 2002 data (Instituto Nacional de Estadísticas Chile 2002), most death certificates (86%) in the country are signed by physicians; in Region II, where Antofagasta is located, the percentage is similar (90%). In addition, Chile has a national health care system that services the whole country (Reichard 1996). Therefore, it is unlikely that differences in diagnostic practices between Antofagasta and the rest of Chile would produce spurious differences in mortality rates.

The importance of ecological studies in causal inference concerning arsenic in drinking water was recognized by the International Agency for Research on Cancer (2004):

For most other known human carcinogens, the major source of causal evidence arise from case-control and cohort studies, with little, if any, evidence from ecological studies. In contrast, for arsenic in drinking-water, ecological studies provide important information on causal inference, because of large exposure contrasts and limited population migration.

There are two reasons why confounding is not a concern, the first reason of which involves the magnitude of the mortality rate ratios identified. Consider, for example, the SMRs for acute myocardial infarction mortality of 2.3 and 2.7 among Antofagasta men for births during 1940–1957 and 1958–1970, respectively. These values are comparable to the acute myocardial infarction mortality rate ratio of 2.11 for current cigarette smokers who smoked > 20 pack-years compared with never-smokers from a large cohort study of about 140,000 men in the United States (Henderson et al. 2007). These similarities suggest that confounding by smoking would explain our SMRs only if all men in Antofagasta smoked but no men in the rest of Chile smoked. Similarly, confounding by smoking would not explain the estimated SMRs for lung cancer, laryngeal cancer, and bladder cancer.

The second reason confounding is not a major concern is that there is no evidence of major differences in risk factors (other than arsenic) between Antofagasta and the rest of Chile. For example, a survey conducted in 1990 indicated that the prevalence of smoking in Region II (27.4% in men and 16.6% in women) was similar to Chile as a whole (26.6% in men and 19.3% in women) (Marshall et al. 2007). It is also extremely unlikely for other confounding factors, including diet or exercise, to produce the magnitude of the SMRs we report here. As shown in Table 1, other cardiovascular mortality risk factors, including body mass index, obesity, cholesterol, and hypertension, were not substantially different between Region II and all of Chile in 2003 (Gobierno de Chile, Ministerio de Salud 2003). Having given consideration to all potential sources of bias, we conclude that our study provides strong epidemiological evidence of increased mortality risks from several causes in young adults exposed to arsenic in early life.

Inorganic arsenic and its metabolites readily pass through the placenta, exposing the fetus to concentrations similar to those of the mother (Concha et al. 1998). Animal experiments have shown that arsenic is a transplacental carcinogen in mice and causes tumors in offspring (Tokar et al. 2011; Waaalke et al. 2007). Vaher (2008) has shown that arsenic acts epigenetically and interferes with DNA methylation. Ren et al. (2010) reported that arsenic exposure may alter DNA methylation, globally affecting the expression of multiple genes; this may explain why exposure to arsenic is associated with multiple disease outcomes in different organs.

We know of no childhood environmental exposure that results in comparable increases in adult mortality rates (Figure 1). Yorifuji et al. (2010) reported that mortality from pancreatic cancer and leukemia were increased in young adults after arsenic exposure from contaminated milk powder in Japan; these exposures were very high and resulted in acute poisoning effects. In a study of 60,182 people, Vineis et al. (2005) reported elevated lung cancer risks from childhood passive smoking, but the relative risk from “daily, many hours” of passive smoking exposure was 3.63 (95% CI: 1.19, 11.11) and there were only four cases of lung cancer in this group. Other studies of passive childhood smoking have not found increased risks (Boffetta et al. 2000). A non-environmental exposure—radiation treatment of childhood cancer—causes major increases in later mortality from other cancers (excluding recurrence of the treated cancer) as well as from noncancer outcomes. A recent report from the Childhood Cancer Survivor Study showed that mortality from other cancers was increased [relative risk (RR) = 2.9; 95% CI: 2.1, 4.2] and that mortality from cardiac causes (RR = 3.3; 95% CI: 2.0, 5.5) and “other” causes (RR = 2.0; 95% CI: 1.3, 3.1) were also increased (Mertens et al. 2008). Increased cancer mortality has also been demonstrated in atomic-bomb survivors exposed in utero or as young children (Preston et al. 2008). Excluding these fairly rare and specific high-dose radiation exposure scenarios, our findings suggest that early-life exposure to arsenic in drinking water results in greater increases in mortality in adults < 50 years of age than those attributable to any other early-life environmental exposure.
Conclusions
To our knowledge, this is the first investigation of all causes of death in young adults following early-life arsenic exposure to arsenic in drinking water. In those exposed to water arsenic concentrations of approximately 870 μg/L, we identified pronounced increases in mortality in young adults 30–49 years of age from cancers of the bladder, larynx, and liver and from renal diseases associated with chronic renal failure. Taken together with the increased mortality from other causes (Smith et al. 2006; Yuan et al. 2007, 2010), the magnitude and extent of the increased mortality we have identified are without precedent for any early-life environmental exposure. Our findings need to be confirmed in other populations, but they add strong support for efforts to reduce population exposure to arsenic in drinking water, particularly during pregnancy and childhood.

References

Argos M, Kaira T, Rathou PJ, Chen Y, Pierce B, Parvez F, et al. 2010. Arsenic exposure from drinking water, and all-cause and chronic-disease mortalities in Bangladesh (HEALS): a prospective cohort study. Lancet 376(9737):252–259.

Boffetta P, Tredaniel J, Greco A. 2000. Risk of childhood cancer and adult lung cancer after childhood exposure to passive smoke: a meta-analysis. Environ Health Perspect 108:73–82.

CASEN. 1990. Illa Encuestra CASEN (Caracterizacion Social Bouse 2000). Risk of childhood cancer and mortality, particularly during pregnancy and childhood. Environ Health Perspect 114:73–83.

Henderson SD, Haiman CA, Wilkens LR, Kolonel LN, Wan P, Pike MC. 2007. Established risk factors account for most of the racial differences in cardiovascular disease mortality. PLoS One 2(4):e000077. doi:10.1371/journal.pone.000077 [Online 18 April 2007].

Instituto Nacional de Estadísticas Chile. 2002. Nacional Censo 2002. Available: http://www.ine.cl/c2002/index.php [accessed 23 August 2012].

International Agency for Research on Cancer. 2004. Some Drinking-water Disinfectants and Contaminants, including Arsenic. IARC Monogr Eval Carcinog Risks Hum 84:1–477.

Liaw J, Marshall G, Ferreccio C, Steinmaus C, Smith AH. 2008. Increased childhood liver cancer mortality and arsenic in drinking water in northern Chile. Cancer Epidemiol Biomark Prev 17:2187–2194.

Selvin S, Liaw J, Friedmann EI, Gomez-Silva B, Caceres-Villanueva L, Yuan Y, Marshall G, Ferreccio C, Steinmaus C, et al. 2007. Fifty-year study of lung and bladder cancer mortality in Chile related to arsenic in drinking water. J Natl Cancer Inst 99(8):605–610.

van Geen A, Ahsan H, Horneman AH, Dray-Renard S, Zhong Y, Hussain I, et al. 2002. Promotion of well-switching to mitigate the current arsenic crisis in Bangladesh. Bull World Health Organ 80:732–737.

Venneurin P. 1991. Determinacion de concentracion de arsenico urinario en diferentes regiones de Chile. In: Primera Jornada sobre Arsenescencia y Ambiental (Ministerio de Salud). Servicio de salud Antofagasta, Departamento de programas sobre el ambiente y salud, Antofagasta, Chile.Republica de Chile, 49–52.

Vineis P, Airoldi L, Velez F, Oligni L, Pastorelli R, Autrup H, et al. 2005. Environmental tobacco smoke and risk of respiratory cancer: a chronic exposure study in adults. Environ Health Perspect 113(10):1324–1333.

Smith AH, Marshall G, Ferreccio C, Steinmaus C, Selvin S, Liaw J, et al. 2007. Acute myocardial infarction mortality in comparison with lung and bladder cancer mortality in arsenic-exposed Region II of Chile from 1955 to 2000. Am J Epidemiol 166(12):1381–1391.

Yuan Y, Marshall G, Ferreccio C, Steinmaus C, Selvin S, Liaw J, et al. 2010. Kidney cancer mortality: fifty-year latency patterns related to arsenic exposure. Epidemiology 21(1):103–108.